Comparison of psoriasis guidelines for use of IL-23 inhibitors in the United States and United Kingdom: a critical appraisal and comprehensive review

References

• Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212.
   PubMed Web of Science ®Google Scholar
• Ighani A, Partridge ACR, Shear NH, et al. Comparison of management guidelines for moderate-to-severe plaque psoriasis: a review of phototherapy, systemic therapies, and biologic agents. J Cutan Med Surg. 2019;23(2):204–221.
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137–174.
   PubMed Web of Science ®Google Scholar
• Stiff KM, Glines KR, Porter CL, et al. Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis. Expert Rev Clin Pharmacol. 2018;11(12):1209–1218.
   PubMed Web of Science ®Google Scholar
• Li W, Ghamrawi R, Haidari W, et al. Risankizumab for the treatment of moderate to severe plaque psoriasis. Ann Pharmacother. 2020;54(4):380–387.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Skyrizi. June 2019.
   Google Scholar
• Smith CH, Yiu ZZ, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 – a rapid update. Br J Dermatol. 2020.DOI:10.1111/bjd.19039
   Google Scholar
• National Institute for Health and Care Excellence. Tildrakizumab for treating moderate to severe plaque psoriasis; April 2019. Available from: https://www.nice.org.uk/guidance/TA575/chapter/1-Recommendations.
   Google Scholar
• National Institute for Health and Care Excellence. Risankizumab for treating moderate to severe plaque psoriasis; August 2019. Available from: https://www.nice.org.uk/guidance/TA596/chapter/1-Recommendations.
   Google Scholar
• National Institute for Health and Care Excellence. Guselkumab for treating moderate to severe plaque psoriasis; June 2018. Available from: https://www.nice.org.uk/guidance/TA521/chapter/1-Recommendations.
   Google Scholar
• Benhadou F, Mintoff D, Schnebert B, et al. Psoriasis and microbiota: a systematic review. Diseases. 2018;6(2):47.
   Google Scholar
• Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(10):1616–1626.
   PubMed Web of Science ®Google Scholar
• Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–130.
   PubMed Web of Science ®Google Scholar
• Senra L, Stalder R, Alvarez Martinez D, et al. Keratinocyte-derived IL-17E contributes to inflammation in psoriasis. J Invest Dermatol. 2016;136(10):1970–1980.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417.
   PubMed Web of Science ®Google Scholar
• Huang YW, Tsai TF. Pharmacological management of pediatric pustular psoriasis. Paediatr Drugs. 2020;22(3):265–277.
   PubMed Web of Science ®Google Scholar
• Carrasquillo OY, Pabón-Cartagena G, Falto-Aizpurua LA, et al. Treatment of erythrodermic psoriasis with biologics: a systematic review. J Am Acad Dermatol. 2020;83(1):151–158.
   PubMed Web of Science ®Google Scholar
• Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114–123.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–288.
   PubMed Web of Science ®Google Scholar
• Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551–1560.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661.
   PubMed Web of Science ®Google Scholar
• Reich K, Gooderham M, Thaçi D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–586.
   PubMed Web of Science ®Google Scholar
• National Psoriasis Foundation. Treatment comparison; June 2019. Available from: https://www.psoriasis.org/sites/default/files/treatment_comparison_chart1.pdf.
   Google Scholar
• Choi YM, Debbaneh M, Weinberg JM, et al. From the Medical Board of the National Psoriasis Foundation: perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2016;75(4):798–805.
   PubMed Web of Science ®Google Scholar